Peptron, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1997-11-21
- Employees
- 99
- Market Cap
- -
- Website
- http://www.peptron.co.kr
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Peptron, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04783636
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
Phase 2
- Conditions
- Early Parkinson's Disease
- Interventions
- Drug: PT320 2.0 mgDrug: PT320 2.0mg PlaceboDrug: PT320 2.5 mg
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Peptron, Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT04269642
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Peptron, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT00964262
- Locations
- 🇰🇷
Clinical Trials Center, Seoul National University Hospital, Seoul, Korea, Republic of
News
No news found